🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma
NCT06903117Advanced Lung Cancer
DrugTargeted CEA CAR-T
Chongqing Precision Biotech Co., Ltd
Phase 1
60
Shanghai
2025-03-24
Recruiting
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
NCT06977893HR+/HER2- Breast Cancer
DrugTislelizumab
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, Ürümqi
2025-03-24
Recruiting
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Chronic Obstructive Pulmonary Disease (COPD): A Translational Application Study
NCT06946953Chronic Obstructive Pulmonary Disease (COPD)
Ruijin Hospital
Phase 1/2
20
Qionghai, Shanghai
2025-03-23
Recruiting
Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients
NCT07741279Anemia of Chronic Kidney Disease, CKD, Non-dialysis Chronic Kidney Disease
DrugEnarodustat
Huashan Hospital
Observational
90
Shanghai
2025-03-23
Active, closed
Intracardiac Echocardiography-Guided Catheter Ablation for Premature Ventricular Contractions Originating From the Papillary Muscles
NCT06898281Premature Ventricular Contractions
Shanghai Chest Hospital
Not applicable
156
Shanghai
2025-03-23
Recruiting
The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children
NCT06890143Pediatric Hereditary Kidney Diseases
DrugDapagliflozin
Children's Hospital of Fudan University
Phase 3
44
Shanghai
2025-03-22
Active, closed
Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations
NCT07711210Infection, Human Immunodeficiency Virus
DrugACC017
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase 1/2
12
Shanghai
2025-03-21
Active, closed
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
NCT06838338Colorectal Cancer
DrugsGlecirasib·Bevacizumab
Jian Li
Phase 1
30
Beijing, Hohhot, Shanghai
2025-03-20
Recruiting
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
NCT06914674Pancreatic Neoplasms
Fudan University
Phase 2
30
Shanghai
2025-03-20
Not yet open
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
NCT05562297Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB, Pancreatic Cancer Stage III
DrugsAbraxane·Sintilimab·Nab-paclitaxel·Gemcitabine
Shanghai Zhongshan Hospital
Phase 2
50
Shanghai
2025-03-20
Active, closed
Transcranial Ultrasound Stimulation as a Neuromodulation Therapy for Craving and Relapse Behaviors in Alcohol Use Disorder.
NCT06867224Alcohol Use Disorder (AUD), Transcranial Ultrasound Stimulation
Shanghai Mental Health Center
Not applicable
40
Shanghai
2025-03-20
Recruiting
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
NCT06860490Hepatocellular Carcinoma (HCC)
DrugsBevacizumab biosimilar·Sintilimab
Fudan University
Phase 2
164
Shanghai
2025-03-18
By invitation
Acupoint Application With Herbal Fumigation and Wash for Preventing Diarrhea-induced Perianal Infection in Allo-HSCT Patients
NCT06912347Allogeneic Hematopoietic Stem Cell Transplantation
Ruijin Hospital
Not applicable
180
Shanghai
2025-03-18
Recruiting
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
NCT06791460Ovarian Cancer Recurrent
DrugsPegylated liposomal doxorubicin·Adebrelimab
Obstetrics & Gynecology Hospital of Fudan University
Phase 2/3
296
Shanghai
2025-03-18
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Beijing, Nanchang, Shanghai, Taiyuan
2025-03-18
Recruiting
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)
NCT06860477Intrahepatic Cholangiocellular Carcinoma
DrugsFolfox·Lenvatinib·Tislelizumab
Fudan University
Phase 2
92
Shanghai
2025-03-18
Active, closed
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
NCT06809530Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4
DrugsIparomlimab and Tuvonralimab·Pemetrexed
Guangzhou Medical University
Phase 1/2
34
Beijing, Huizhou, Shanghai
2025-03-17
Not yet open
Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis
NCT06874673Pronase, Mucosal Clarity
DrugPronase
Changhai Hospital
Not applicable
438
Shanghai
2025-03-17
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
NCT06857227Rheumatoid Arthritis
DrugGNC-038
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
54
Shanghai
2025-03-17
Recruiting
MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors
NCT07004647Peritoneal Tumor
Ruijin Hospital
Not applicable
10
Shanghai
2025-03-15
Recruiting
Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
NCT06878222Cervical Cancers
Obstetrics & Gynecology Hospital of Fudan University
Phase 2
35
Shanghai
2025-03-15
Active, closed
A Randomized Clinical Trial on the Effectiveness of Novel Plano Spectacle Lenses on Myopia Prevention in Pre-myopic Children
NCT06860737Myopic Children
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
388
Shanghai
2025-03-15
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
DrugFaricimab
Hoffmann-La Roche
Phase 4
274
Beijing, Chengdu, Guangzhou, Shanghai, Wuhan
2025-03-14
Recruiting
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551Juvenile Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
60
Beijing, Chongqing, Guangzhou, Nanjing, Changchun, Hangzhou, Shanghai
2025-03-13
Recruiting
Lecanemab for Early Onset Familial Alzheimer's Disease
NCT06883019Alzheimer Disease
RenJi Hospital
Observational
114
Beijing, Guangdong, Guizhou, Jiangsu, Shanghai, Sichuan, Tianjin, Zhejiang
2025-03-13
Recruiting
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.
NCT07107633Solid Tumor, Peritoneal Metastasis
Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Phase 2
90
Shanghai
2025-03-12
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsVolrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Beijing, Chengdu, Harbin, Shanghai, Wuhan, Zhengzhou
2025-03-12
Recruiting
Effect of Bone Augmentation Simultaneous to Implant Removal on the Prognosis of Reimplantation at the Same Site
NCT07078890Implant Failure, Bone Augmentation, Prognosis
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
40
Wuhan, Hangzhou, Shanghai
2025-03-12
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Beijing, Chongqing, Shijiazhuang, Nanjing, Suzhou, Xi'an, Xianyang, Shanghai
2025-03-11
By invitation
Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
NCT06984055Esophageal Cancer, Squamous Cell
Changhai Hospital
Observational
600
Shanghai
2025-03-11
Recruiting
Universal CAR-T Cell Therapy for NHL
NCT07248163Non-hodgkin Lymphoma,B Cell
DrugBRL-301
Bioray Laboratories
Not applicable
6
Shanghai
2025-03-11
Recruiting
Translation and Validation of Chinese COMPAT-SF
NCT06917716Chronic Pancreatitis
Changhai Hospital
Observational
356
Shanghai
2025-03-10
Active, closed
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06866548mCRPC
DrugTislelizumab
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
7
Shanghai
2025-03-10
Recruiting
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
NCT06928584Locally Recurrent Rectal Cancer
Fudan University
Phase 2
221
Shanghai
2025-03-10
Recruiting
A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.
NCT06788431Atherosclerosis
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase EARLY_PHASE1
18
Nanyang, Shanghai
2025-03-10
Not yet open
ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer
NCT06878196Uterine Cervical Neoplasm
DrugCadonilimab
Obstetrics & Gynecology Hospital of Fudan University
Not applicable
20
Shanghai
2025-03-10
By invitation
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
NCT06888661Spinal Muscular Atrophy (SMA)
Guangzhou Jiayin Biotech Ltd
Phase EARLY_PHASE1
4
Shanghai
2025-03-10
Recruiting
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
NCT07183865Locally Recurrent Rectal Cancer
Fudan University
Phase 2
44
Shanghai
2025-03-09
Not yet open
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
NCT06869174Cancer of Unknown Primary
DrugsMRG002·Pucotenlimab
Zhiguo Luo, MD, PhD
Phase 2
50
Shanghai
2025-03-08
Active, closed
Emulsion 8-Week Anti-acne Efficacy Clinical Study
NCT06985745Female, Male, Acne
ChinaNorm
Not applicable
66
Shanghai
2025-03-08
Active, closed
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
NCT06762080Leptomeningeal Metastasis
DrugsCadonilimab·Pemetrexed
Guangzhou Medical University
Phase 1/2
36
Huizhou, Beijing, Shanghai
2025-03-07
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
DrugALXN2030
Alexion Pharmaceuticals, Inc.
Phase 2
47
Changsha, Guangzhou, Nanning, Shanghai, Wuhan, Xi'an
2025-03-07
Recruiting
Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
NCT07362914Breast Cancer
DrugsDoxorubicin Hydrochloride Liposome·Dexamethasone·Cyclophosphamide
Fudan University
Phase 3
182
Shanghai
2025-03-07
Recruiting
Induced Pluripotent Stem Cells-derived Small Extracellular Vesicles May Promote Neurological Function and Improve Cognitive Impairment in Acute Ischemic Stroke Patients
NCT07145294Cognitive Impairment
DrugIEV
Hongmei Wang
Phase 1/2
40
Shanghai
2025-03-07
Recruiting
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
NCT06796699Advanced Solid Tumors With MTAP Gene Deletion
Suzhou Genhouse Bio Co., Ltd.
Phase 1
90
Beijing, Shanghai, Taiyuan
2025-03-07
Recruiting
Bilateral Single-Electrode VO Combined With STN-DBS for Treating Meige Syndrome
NCT06912282Meige Syndrome
Huashan Hospital
Not applicable
20
Shanghai
2025-03-06
Recruiting
Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors
NCT06823609Advanced Malignant Tumor
DrugQLS1304
Qilu Pharmaceutical Co., Ltd.
Phase 1
180
Shanghai
2025-03-06
Recruiting
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.
Phase 1
96
Fuzhou, Guangzhou, Shanghai, Chengdu
2025-03-06
Active, closed
Impact of Periodontal Therapy on AF Recurrence Post-Ablation in High-Inflammatory Burden Patients
NCT06892808Atrial Fibrillation, Periodontitis
Xu Liu
Not applicable
212
Shanghai
2025-03-05
Recruiting
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
NCT06541639Advanced or Recurrent Solid Tumors
DrugTislelizumab
Peking University
Phase 1
78
Beijing, Shanghai
2025-03-04
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06955988Locally Advanced or Metastatic Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 1
120
Shanghai
2025-03-04
Not yet open
Deep Sedation in Catheter Ablation of Atrial Fibrillation
NCT06836999Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation
The First Affiliated Hospital of Dalian Medical University
Not applicable
1,334
Hefei, Guangzhou, Nanjing, Suzhou, Nanchang, Dalian, Qingdao, Shanghai
2025-03-03
By invitation
A Study on Multimodal Prognostic Scoring of Advanced PDAC.
NCT07373691Pancreatic Ductal Adenocarcinoma (PDAC)
RenJi Hospital
Observational
100
Shanghai
2025-03-02
Recruiting
A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.
NCT06839131Healthy Participants
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
94
Shanghai
2025-03-02
Recruiting
Clinical Analysis of the Antihypertensive Effect of Laparoscopic Peripheral Nerve Blockade of the Renal Artery in Patients With Retroperitoneal Disease and Hypertension
NCT06829134Hypertension, Retroperitoneal Disease
Ruijin Hospital
Not applicable
246
Shanghai
2025-03-01
Not yet open
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
NCT06863441T-NK Cell Lymphoma
Ruijin Hospital
Observational
50
Shanghai
2025-03-01
Active, closed
High-dose Intravenous Vitamin C for the Treatment of Severe Acute Pancreatitis
NCT06897384Severe Acute Pancreatitis
Ruijin Hospital
Not applicable
388
Shanghai
2025-03-01
Recruiting
Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques
NCT06687408Lung Cancer, Non-Small Cell
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
450
Hangzhou, Shanghai
2025-03-01
Recruiting
A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases
NCT06901817Leptomeningeal Metastasis
Shanghai Cancer Hospital, China
Phase 2
97
Shanghai
2025-03-01
Recruiting
Perioperative Immunotherapy for Resectable Limited-Stage SCLC
NCT07109401Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer
DrugTislelizumab
Fudan University
Phase 2
37
Shanghai
2025-03-01
Recruiting
Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension
NCT06970509Esophageal Varices, Portal Hypertension
Shanghai Zhongshan Hospital
Observational
1,450
Guangzhou, Nanchang, Shenyang, Jinan, Shanghai
2025-03-01
Recruiting
Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air
NCT06968234Cirrhosis, Microbiota, Breath Tests
Shanghai Zhongshan Hospital
Observational
1,000
Shanghai
2025-03-01
Recruiting
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
NCT06521866Advanced Colorectal Carcinoma, Immunotherapy
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Recruiting
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
NCT07482020Atrial Fibrillation (AF), Hypertension
Huashan Hospital
Phase 2
66
Shanghai
2025-03-01
Recruiting
A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSP
NCT06936163Hereditary Spastic Paraplegia
Shanghai 6th People's Hospital
Observational
100
Shanghai
2025-03-01
Not yet open
Predicting Gastric Neoplasia in Patients with High-risk Endoscopic Features
NCT06853509Gastric Neoplasia
Fudan University
Observational
2,700
Shanghai
2025-03-01
Not yet open
Rituximab in the First Episode of Paediatric Nephrotic Syndrome
NCT05850546Steroid-Sensitive Nephrotic Syndrome
DrugsPrednisolone/Prednisone·Rituximab
Children's Hospital of Fudan University
Phase 3
138
Shanghai
2025-03-01
Recruiting
Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
NCT07054086Esophageal Cancer
Shanghai Zhongshan Hospital
Observational
30
Shanghai
2025-03-01
Active, closed
An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease
NCT06778265Parkinson Disease, Idiopathic
Shanghai UniXell Biotechnology Co., Ltd
Phase 1
12
Shanghai
2025-03-01
Not yet open
Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes
NCT06847178Diabetes, Type 2 Diabetes
Shanghai Changzheng Hospital
Phase 2/3
60
Shanghai
2025-03-01
Recruiting
DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC
NCT06846762Non-Small Cell Lung Cancer
Baohui Han
Observational
508
Shanghai
2025-03-01
Not yet open
Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction
NCT06597682Post-acute Sequelae of SARS-COV-2 Infection
DrugsBudesonide/Formoterol·Vitamin C·Prednisone
Huashan Hospital
Not applicable
632
Shanghai
2025-03
Recruiting
KPD Consolidation After ASCT in NDMM Patients
NCT06879379Multiple Myeloma, Newly Diagnosed
Peking University People's Hospital
Phase 2/3
202
Beijing, Shanghai
2025-03
By invitation
A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA
NCT06588803Spinal Muscular Atrophy
Guangzhou Jiayin Biotech Ltd
Observational
18
Shanghai
2025-03
Recruiting
Research on Wireless Brain Implant System for General Control of External Devices
NCT06829212Complete or Incomplete Paraplegia/quadriplegia, Spinal Cord Injury, Brainstem Stroke, Amyotrophic Lateral Sclerosis
Shanghai StairMed Technology Co., Ltd.
Not applicable
4
Shanghai
2025-03
Recruiting
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis
NCT06570291Knee Osteoarthritis
DrugSodium Hyaluronate
Wuxi Cellular Biopharmaceutical Group Ltd.
Phase 3
520
Shanghai
2025-02-28
Recruiting
Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
NCT06967038Primary Sjogren's Syndrome, Lymphoma
Bangdong Gong
Phase 1/2
6
Shanghai
2025-02-28
Recruiting
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
NCT06856200Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy
DrugsPalbociclib·Fulvestrant·Paclitaxel
Fudan University
Not applicable
36
Shanghai
2025-02-28
Recruiting
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
NCT06856187Metastatic Colorectal Cancer (CRC)
DrugsTrifluridine/Tipiracil·Bevacizumab
Fudan University
Phase 2
119
Shanghai
2025-02-28
Not yet open
Real-World Study of Myopia Prevention and Control in Children
NCT06849895Myopia, Refractive Errors, Children, Cohort
Shanghai Eye Disease Prevention and Treatment Center
Observational
15,000
Shanghai
2025-02-28
Not yet open
AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NCT06860789Chemotherapy-induced Peripheral Neuropathy (CIPN)
Akeso
Phase 1
85
Guangzhou, Shanghai
2025-02-28
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
Pathogen Detection in Infectious Uveitis
NCT04521673Infectious Panuveitis, Infectious Iridocyclitis
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
100
Shanghai
2025-02-26
Recruiting
Evolution of Intracardiac Electrograms Recorded by Left Bundle Branch Pacing Lead in Patients With ICD or CRT-D
NCT06745778Ventricular Tachycardia (VT), Ventricular Fibrillation
Medtronic Cardiac Rhythm and Heart Failure
Observational
50
Wenzhou, Shanghai
2025-02-26
Recruiting
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT06873659Solid Tumor, Gastric Cancer, Liver Cancer
Qurgen Inc.
Phase 1
96
Beijing, Lanzhou, Guangzhou, Nanjing, Xi'an, Jinan, Shanghai, Hangzhou
2025-02-26
Recruiting
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
NCT06778031HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
54
Harbin, Shanghai
2025-02-26
Recruiting
Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
NCT06763029Colorectal Cancer Metastatic
Fudan University
Phase 2
36
Shanghai
2025-02-26
Recruiting
Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis
NCT06519591Gastric Cancer Stage IV, Peritoneal Metastases
Ruijin Hospital
Phase 2
40
Shanghai
2025-02-25
Recruiting
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
NCT06849986Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
DrugsIfosfamide·Liposomal doxorubicin·Tislelizumab
Fudan University
Phase 2
45
Shanghai
2025-02-25
Active, closed
Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
NCT06842563Hepatocellular Carcinoma (HCC)
Singlera Genomics Inc.
Observational
900
Shanghai
2025-02-25
Not yet open
Standardized Antihypertensive Treatment Protocol
NCT06790927Hypertension
Shanghai Jiao Tong University School of Medicine
Not applicable
400
Shanghai
2025-02-24
Not yet open
Efficacy and Safety of Pulsed Field Ablation in Refractory Mitral Isthmus-dependent Atrial Flutter: Pulsed Field Ablation Vs. Radiofrequency Ablation: a Preliminary Randomized Controlled Study
NCT06850064Atrial Fibrillation (AF)
Shanghai Chest Hospital
Not applicable
60
Shanghai
2025-02-24
Recruiting
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
NCT06838273Non-small Cell Lung Cancer
DrugsIza-bren·Osimertinib
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
720
Shanghai
2025-02-24
Recruiting
Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease
NCT06388863Parkinson Disease
Shanghai Zhongshan Hospital
Not applicable
76
Shanghai
2025-02-21
Recruiting
Risk Factors for Inadequate Bowel Preparation Before Colonoscopy
NCT06878378Colonoscopy, Colonoscopy: Bowel Preparation
Changhai Hospital
Observational
10,000
Shanghai
2025-02-21
Recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06889688Breast Cancer Stage IV, Triple -Negative Breast Cancer
DrugsEribulin·Apatinib·Camrelizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Recruiting
A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients
NCT07641686Hair Transplantation, Seborrheic Dermatitis, Scalp Care
ChinaNorm
Not applicable
120
Shanghai
2025-02-21
Recruiting
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
NCT06796803Potentially Resectable Hepatocellular Carcinoma
DrugsRivoceranib·Camrelizumab
Shanghai Zhongshan Hospital
Phase 2/3
398
Harbin, Shanghai
2025-02-20
Recruiting
Coronary Aspiration Catheter Clinical Trial
NCT06951724ST-segment Elevation Myocardial Infarction (STEMI)
BrosMed Medical Co., Ltd
Not applicable
144
Shanghai
2025-02-20
Rows per page Showing 1701–1800 of 3827
Previous 16 17 18 19 20 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=18

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.